Schizophrenia Drugs Market by Therapeutic Class - Global Industry Analysis and Forecast to 2023

Published On : December 2017 Pages : 100 Category: Pharmaceuticals Report Code : HC12414

Industry Outlook and Trend Analysis

The Schizophrenia Drugs Market was worth USD 6.35 billion in the year of 2014 and is expected to reach approximately USD 8.04 billion by 2023, while registering itself at a compound annual growth rate (CAGR) of 2.65% during the forecast period. Schizophrenia is a chronic disorder of the central nervous system, influences 1.0% of the worldwide populace or seven out of 1,000 people. The confusion portrayed by side effects, for example, thought disorders, hallucinations, inability to execute day-to day functions is known to develop from a combination of chemical, environmental and genetic factors. Rising number of patients looking for treatment and rising interest for enhanced healthcare infrastructure are foreseen to drive the market. The schizophrenia market stays packed with solid neglected needs. There is a requirement for advancement for the treatment of this crippling disorder. The report examines about developing markets in the Asia Pacific region. India and China are rising as an open door for market extension. Factors, for example, useful medicinal services, increased health awareness, large aging population, and low-cost are the real driving variables for market extension in these two nations.

Therapeutic Class Outlook and Trend Analysis

The drugs that are prescribed for schizophrenia can be fragmented by therapeutic class into first, second and third-generation antipsychotics. Presently, second-generation and third-generation antipsychotics remain the standard of care in the schizophrenia treatment market. The report features brands recommended for the treatment of schizophrenia, for example, Saphris, Zyprexa, Abilify, Seroquel, Vraylar, Saphris, Aristada, Fanapt among others. Long-Acting Injectables (LAIs) are progressively being produced as they offer a few points of interest, for example, diminished hospitalizations and enhanced treatment result. The variables limiting the development of worldwide schizophrenia drugs market would be strict control around new product endorsements and rising generic dispatches.

Regional Outlook and Trend Analysis

Japan is assessed to encounter the speediest development over the conjecture time frame because of enhanced healthcare infrastructure, increasing awareness about early diagnosis, rising disposable income, and accessibility of successful treatment. The worldwide schizophrenia drugs market will be driven by the developing awareness about mental issue, expanded use on medicinal services and accessibility of powerful treatment strategies with interest for tailored and target specific medications.

Competitive Insights

The leading players in the market are Eli Lilly and Company, Bristol-Myers Squibb, Dainippon Sumitomo Pharma Co Ltd, Vanda Pharma, Johnson & Johnson, Alkermes, Allergan and AstraZeneca. Johnson & Johnson, Otsuka and Lundbeck are concentrating on developing the schizophrenia therapeutics market for Long-Acting Injectables and are anticipated to possess tremendous position in the schizophrenia therapeutics market.

The Schizophrenia Drugs Market is segmented as follows-

By Therapeutic Class:

  • Second-Generation Antipsychotics
    • Invega (Paliperidone)
    • Geodon (Ziprasidone)
    • Latuda (Lurasidone)
    • Fanapt (Iloperidone)
    • Vraylar (Cariprazine)
    • Risperdal (Risperidone)
    • Zyprexa (Olanzapine)
    • Seroquel (Quetiapine)
    • Aristada (Aripiprazole Lauroxil)
    • Saphris (Asenapine)
  • Third-Generation Antipsychotics
    • Abilify (Aripiprazole)
  • Others
    • Generics
    • First-Generation Antipsychotics

By Region

  • North America
  • U.S
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • China
  • Australia
  • India
  • South Korea
  • Rest of Asia Pacific
  • Rest of the World
  • Brazil
  • South Africa
  • Saudi Arabia
  • United Arab Emirates
  • Others

Some of the key questions answered by the report are:

  • What was the market size in 2014 and forecast from 2015 to 2023?
  • What will be the industry market growth from 2015 to 2023?
  • What are the major drivers, restraints, opportunities, challenges, and industry trends and their impact on the market forecast?
  • What are the major segments leading the market growth and why?
  • Which are the leading players in the market and what are the major strategies adopted by them to sustain the market competition?

Market Classification

  • Schizophrenia Drugs Market , By Therapeutic Class, Estimates and Forecast, 2014-2023($Million)
  • Second-Generation Antipsychotics
  • Invega (Paliperidone)
  • Geodon (Ziprasidone)
  • Latuda (Lurasidone)
  • Fanapt (Iloperidone)
  • Vraylar (Cariprazine)
  • Risperdal (Risperidone)
  • Zyprexa (Olanzapine)
  • Seroquel (Quetiapine)
  • Aristada (Aripiprazole Lauroxil)
  • Saphris (Asenapine)
  • Third-Generation Antipsychotics
  • Abilify (Aripiprazole)
  • Others
  • Generics
  • First-Generation Antipsychotics
  • Schizophrenia Drugs Market , By Region, Estimates and Forecast, 2014-2023($Million)
    • North America
  • North America Schizophrenia Drugs Market , By Country
  • North America Schizophrenia Drugs Market , By Therapeutic Class
    • U.S. Schizophrenia Drugs Market , By Therapeutic Class
    • Canada Schizophrenia Drugs Market , By Therapeutic Class
    • Mexico Schizophrenia Drugs Market , By Therapeutic Class
    • Europe
  • Europe Schizophrenia Drugs Market , By Country
  • Europe Schizophrenia Drugs Market , By Therapeutic Class
    • Germany Schizophrenia Drugs Market , By Therapeutic Class
    • France Schizophrenia Drugs Market , By Therapeutic Class
    • UK Schizophrenia Drugs Market , By Therapeutic Class
    • Italy Schizophrenia Drugs Market , By Therapeutic Class
    • Spain Schizophrenia Drugs Market , By Therapeutic Class
    • Rest of Europe Schizophrenia Drugs Market , By Therapeutic Class
    • Asia-Pacific
      • Asia-Pacific Schizophrenia Drugs Market , By Country
      • Asia-Pacific Schizophrenia Drugs Market , By Therapeutic Class
        • Japan Schizophrenia Drugs Market , By Therapeutic Class
        • Australia Schizophrenia Drugs Market , By Therapeutic Class
        • India Schizophrenia Drugs Market , By Therapeutic Class
        • South Korea Schizophrenia Drugs Market , By Therapeutic Class
        • Rest of Asia-Pacific Schizophrenia Drugs Market , By Therapeutic Class
    • Rest of the World
      • Rest of the World Schizophrenia Drugs Market , By Country
      • Rest of the World Schizophrenia Drugs Market , By Therapeutic Class
        • Brazil Schizophrenia Drugs Market , By Therapeutic Class
        • South Africa Schizophrenia Drugs Market , By Therapeutic Class
        • Saudi Arabia Schizophrenia Drugs Market , By Therapeutic Class
        • Turkey Schizophrenia Drugs Market , By Therapeutic Class
        • United Arab Emirates Schizophrenia Drugs Market , By Therapeutic Class
        • Others Schizophrenia Drugs Market , By Therapeutic Class

1.      Introduction

1.1.      Report Description

1.2.      Research Methodology

1.2.1. Secondary Research

1.2.2. Primary Research

2.      Executive Summary

2.1.      Key Highlights

3.      Market Overview

3.1.      Introduction

3.1.1. Market Definition

3.1.2. Market Segmentation

3.2.      Market Dynamics

3.2.1. Drivers

3.2.1.1.   Rising Demand for Improved Healthcare Infrastructure

3.2.1.2.   Growing  Health Awareness

3.2.2. Restraints

3.2.2.1.   Availability of Low Cost Substitute

3.2.3. Opportunities

3.2.3.1.   Emerging Markets to Offer Lucrative Growth Opportunities

4.      Schizophrenia Drugs Market,By Therapeutic Class

4.1.      Introduction

4.2.      Schizophrenia Drugs Market  Assessment and Forecast, By Therapeutic Class, 2014-2023

4.3.      Second-Generation Antipsychotics

4.3.1. Market Assessment and Forecast, By Type, 2014-2023 ($Million)

4.3.2. Market Assessment and Forecast, By Region, 2014-2023 ($Million)

4.3.3. Invega (Paliperidone)

4.3.3.1.   Market Assessment and Forecast, By Region, 2014-2023 ($Million)

4.3.4. Geodon (Ziprasidone)

4.3.4.1.   Market Assessment and Forecast, By Region, 2014-2023 ($Million)

4.3.5. Latuda (Lurasidone)

4.3.5.1.   Market Assessment and Forecast, By Region, 2014-2023 ($Million)

4.3.6. Fanapt (Iloperidone)

4.3.6.1.   Market Assessment and Forecast, By Region, 2014-2023 ($Million)

4.3.7. Vraylar (Cariprazine)

4.3.7.1.   Market Assessment and Forecast, By Region, 2014-2023 ($Million)

4.3.8. Risperdal (Risperidone)

4.3.8.1.   Market Assessment and Forecast, By Region, 2014-2023 ($Million)

4.3.9. Zyprexa (Olanzapine)

4.3.9.1.   Market Assessment and Forecast, By Region, 2014-2023 ($Million)

4.3.10.    Seroquel (Quetiapine)

4.3.10.1.              Market Assessment and Forecast, By Region, 2014-2023 ($Million)

4.3.11.    Aristada (Aripiprazole Lauroxil)

4.3.11.1.              Market Assessment and Forecast, By Region, 2014-2023 ($Million)

4.3.12.    Saphris (Asenapine)

4.3.12.1.              Market Assessment and Forecast, By Region, 2014-2023 ($Million)

4.4.      Third-Generation Antipsychotics

4.4.1. Market Assessment and Forecast, By Type, 2014-2023 ($Million)

4.4.2. Market Assessment and Forecast, By Region, 2014-2023 ($Million)

4.4.3. Abilify (Aripiprazole)

4.4.3.1.   Market Assessment and Forecast, By Region, 2014-2023 ($Million)

4.5.      Others

4.5.1. Market Assessment and Forecast, By Type, 2014-2023 ($Million)

4.5.2. Market Assessment and Forecast, By Region, 2014-2023 ($Million)

4.5.3. Generics

4.5.3.1.   Market Assessment and Forecast, By Region, 2014-2023 ($Million)

4.5.4. First-Generation Antipsychotics

4.5.4.1.   Market Assessment and Forecast, By Region, 2014-2023 ($Million)

5.      Schizophrenia Drugs Market,By Region

5.1.      Introduction

5.2.      Schizophrenia Drugs Market   Assessment and Forecast, By Region, 2014-2023 ($Million)

5.3.      North America

5.3.1. Market Assessment and Forecast, By Country, 2014-2023 ($Million)

5.3.2. Market Assessment and Forecast, By Therapeutic Class, 2014-2023 ($Million)

5.3.3. U.S.

5.3.3.1.   Market Assessment and Forecast, By Therapeutic Class, 2014-2023 ($Million)

5.3.4. Canada

5.3.4.1.   Market Assessment and Forecast, By Therapeutic Class, 2014-2023 ($Million)

5.3.5. Mexico

5.3.5.1.   Market Assessment and Forecast, By Therapeutic Class, 2014-2023 ($Million)

5.4.      Europe

5.4.1. Market Assessment and Forecast, By Country, 2014-2023 ($Million)

5.4.2. Market Assessment and Forecast, By Therapeutic Class, 2014-2023 ($Million)

5.4.3. Germany

5.4.3.1.   Market Assessment and Forecast, By Therapeutic Class, 2014-2023 ($Million)

5.4.4. France

5.4.4.1.   Market Assessment and Forecast, By Therapeutic Class, 2014-2023 ($Million)

5.4.5. UK

5.4.5.1.   Market Assessment and Forecast, By Therapeutic Class, 2014-2023 ($Million)

5.4.6. Italy

5.4.6.1.   Market Assessment and Forecast, By Therapeutic Class, 2014-2023 ($Million)

5.4.7. Spain

5.4.7.1.   Market Assessment and Forecast, By Therapeutic Class, 2014-2023 ($Million)

5.4.8. Rest of Europe

5.4.8.1.   Market Assessment and Forecast, By Therapeutic Class, 2014-2023 ($Million)

5.5.      Asia-Pacific

5.5.1. Market Assessment and Forecast, By Country, 2014-2023 ($Million)

5.5.2. Market Assessment and Forecast, By Therapeutic Class, 2014-2023 ($Million)

5.5.3. Japan

5.5.3.1.   Market Assessment and Forecast, By Therapeutic Class, 2014-2023 ($Million)

5.5.4. China

5.5.4.1.   Market Assessment and Forecast, By Therapeutic Class, 2014-2023 ($Million)

5.5.5. Australia

5.5.5.1.   Market Assessment and Forecast, By Therapeutic Class, 2014-2023 ($Million)

5.5.6. India

5.5.6.1.   Market Assessment and Forecast, By Therapeutic Class, 2014-2023 ($Million)

5.5.7. South Korea

5.5.7.1.   Market Assessment and Forecast, By Therapeutic Class, 2014-2023 ($Million)

5.5.8. Rest of Asia-Pacific

5.5.8.1.   Market Assessment and Forecast, By Therapeutic Class, 2014-2023 ($Million)

5.6.      Rest of the World

5.6.1. Market Assessment and Forecast, By Country, 2014-2023 ($Million)

5.6.2. Market Assessment and Forecast, By Therapeutic Class, 2014-2023 ($Million)

5.6.3. Brazil

5.6.3.1.   Market Assessment and Forecast, By Therapeutic Class, 2014-2023 ($Million)

5.6.4. Turkey

5.6.4.1.   Market Assessment and Forecast, By Therapeutic Class, 2014-2023 ($Million)

5.6.5. Saudi Arabia

5.6.5.1.   Market Assessment and Forecast, By Therapeutic Class, 2014-2023 ($Million)

5.6.6. South Africa

5.6.6.1.   Market Assessment and Forecast, By Therapeutic Class, 2014-2023 ($Million)

5.6.7. United Arab Emirates

5.6.7.1.   Market Assessment and Forecast, By Therapeutic Class, 2014-2023 ($Million)

5.6.8. Others

5.6.8.1.   Market Assessment and Forecast, By Therapeutic Class, 2014-2023 ($Million)

6.      Company Profiles

6.1.      Johnson & Johnson

6.1.1. Business Overview

6.1.2. Product Portfolio

6.1.3. Key Financials

6.1.4. Strategic Developments

6.2.       Bristol-Myers Squibb and Company/ Otsuka Pharmaceuticals

6.2.1. Business Overview

6.2.2. Product Portfolio

6.2.3. Key Financials

6.2.4. Strategic Developments

6.3.      AstraZeneca

6.3.1. Business Overview

6.3.2. Product Portfolio

6.3.3. Key Financials

6.3.4. Strategic Developments

6.4.      Eli Lilly

6.4.1. Business Overview

6.4.2. Product Portfolio

6.4.3. Key Financials

6.4.4. Strategic Developments

6.5.      Alkermes

6.5.1. Business Overview

6.5.2. Product Portfolio

6.5.3. Strategic Developments

6.6.      Sumitomo Dainippon Pharma

6.6.1. Business Overview

6.6.2. Product Portfolio

6.6.3. Strategic Developments

6.7.      Pfizer

6.7.1. Business Overview

6.7.2. Product Portfolio

6.7.3. Strategic Developments

6.8.      Vanda Pharmaceuticals

6.8.1. Business Overview

6.8.2. Product Portfolio

6.8.3. Strategic Developments

6.9.      Allergan (Forest Labs)/ Geodon Ritcher

6.9.1. Business Overview

6.9.2. Product Portfolio

6.9.3. Key Financials

 

6.9.4. Strategic Developments


List of Tables

Table 1.Schizophrenia Drugs Market, By Therapeutic Class ($Million), 2014-2023
Table 2.Second-Generation Antipsychoticsl Market, By Type ($Million), 2014-2023
Table 3.Second-Generation Antipsychotics Market, By Region ($Million), 2014-2023
Table 4.Invega (Paliperidone) Market, By Region ($Million), 2014-2023
Table 5.Geodon (Ziprasidone) Market, By Region ($Million), 2014-2023
Table 6.Latuda (Lurasidone) Market, By Region ($Million), 2014-2023
Table 7.Fanapt (Iloperidone) Market, By Region ($Million), 2014-2023
Table 8.Vraylar (Cariprazine) Market, By Region ($Million), 2014-2023
Table 9.Risperdal (Risperidone) Market, By Region ($Million), 2014-2023
Table 10.Zyprexa (Olanzapine) Market, By Region ($Million), 2014-2023
Table 11.Seroquel (Quetiapine) Market, By Region ($Million), 2014-2023
Table 12.Aristada (Aripiprazole Lauroxil) Market, By Region ($Million), 2014-2023
Table 13.Saphris (Asenapine) Market, By Region ($Million), 2014-2023
Table 14.Third-Generation Antipsychotics Market, By Type ($Million), 2014-2023
Table 15.Third-Generation Antipsychotics Market, By Region ($Million), 2014-2023
Table 16.Abilify (Aripiprazole) Market, By Region ($Million), 2014-2023
Table 17.Others Market, By Type ($Million), 2014-2023
Table 18.Others Market, By Region ($Million), 2014-2023
Table 19.Generics Market, By Region ($Million), 2014-2023
Table 20.First-Generation Antipsychotics Market, By Region ($Million), 2014-2023
Table 21.North America Schizophrenia Drugs Market, By Country, 2014-2023 ($Million)
Table 22.North America Schizophrenia Drugs Market, By Therapeutic Class, 2014-2023 ($ Million)
Table 23.U.S.Schizophrenia Drugs Market, By Therapeutic Class, 2014-2023 ($ Million)
Table 24.Canada Schizophrenia Drugs Market, By Therapeutic Class, 2014-2023 ($ Million)
Table 25.Mexico Schizophrenia Drugs Market, By Therapeutic Class, 2014-2023 ($ Million)
Table 26.Europe Schizophrenia Drugs Market, By Country, 2014-2023 ($Million)
Table 27.Europe Schizophrenia Drugs Market, By Therapeutic Class, 2014-2023 ($ Million)
Table 28.Germany Schizophrenia Drugs Market, By Therapeutic Class, 2014-2023 ($ Million)
Table 29.France Schizophrenia Drugs Market, By Therapeutic Class, 2014-2023 ($ Million)
Table 30.UK Schizophrenia Drugs Market, By Therapeutic Class, 2014-2023 ($ Million)
Table 31.Italy Schizophrenia Drugs Market, By Therapeutic Class, 2014-2023 ($ Million)
Table 32.Spain Schizophrenia Drugs Market, By Therapeutic Class, 2014-2023 ($ Million)
Table 33.Rest of Europe Schizophrenia Drugs Market, By Therapeutic Class, 2014-2023 ($ Million)
Table 34.Asia-Pacific Schizophrenia Drugs Market, By Country, 2014-2023 ($Million)
Table 35.Asia-Pacific Schizophrenia Drugs Market, By Therapeutic Class, 2014-2023 ($ Million)
Table 36.Japan Schizophrenia Drugs Market, By Therapeutic Class, 2014-2023 ($ Million)
Table 37.China Schizophrenia Drugs Market, By Therapeutic Class, 2014-2023 ($ Million)
Table 38.Australia Schizophrenia Drugs Market, By Therapeutic Class, 2014-2023 ($ Million)
Table 39.India Schizophrenia Drugs Market, By Therapeutic Class, 2014-2023 ($ Million)
Table 40.South Korea Schizophrenia Drugs Market, By Therapeutic Class, 2014-2023 ($ Million)
Table 41.Rest of Asia-Pacific Schizophrenia Drugs Market, By Therapeutic Class, 2014-2023 ($ Million)
Table 42.Rest of the World Schizophrenia Drugs Market, By Country, 2014-2023 ($Million)
Table 43.Rest of the World Schizophrenia Drugs Market, By Therapeutic Class, 2014-2023 ($ Million)
Table 44.Brazil Schizophrenia Drugs Market, By Therapeutic Class, 2014-2023 ($ Million)
Table 45.Turkey Schizophrenia Drugs Market, By Therapeutic Class, 2014-2023 ($ Million)
Table 46.Saudi Arabia Schizophrenia Drugs Market, By Therapeutic Class, 2014-2023 ($ Million)
Table 47.South Africa Schizophrenia Drugs Market, By Therapeutic Class, 2014-2023 ($ Million)
Table 48.United Arab Emirates Schizophrenia Drugs Market, By Therapeutic Class, 2014-2023 ($ Million)
Table 49.Others Schizophrenia Drugs Market, By Therapeutic Class, 2014-2023 ($ Million)
Table 50.Johnson & Johnson: Key Strategic Developments, 2015-2017
Table 51.Bristol-Myers Squibb and Company/ Otsuka Pharmaceuticals: Key Strategic Developments, 2015-2017
Table 52.AstraZeneca: Key Strategic Developments, 2015-2017
Table 53.Eli Lilly: Key Strategic Developments, 2015-2017
Table 54.Alkermes: Key Strategic Developments, 2015-2017
Table 55.Sumitomo Dainippon Pharma: Key Strategic Developments, 2015-2017
Table 56.Sumitomo Dainippon Pharma: Key Strategic Developments, 2015-2017
Table 57.Vanda Pharmaceuticals: Key Strategic Developments, 2015-2017
Table 58.Allergan (Forest Labs)/ Geodon Ritcher: Key Strategic Developments, 2015-2017


List of Figures

Figure 1.Schizophrenia Drugs Market Share, By Therapeutic Class, 2014 & 2023
Figure 2Schizophrenia Drugs Market, By Region, 2014 & 2023($Million)
Figure 3.Johnson & Johnson: Net Revenues, 2014-2016 ($Million)
Figure 4.Johnson & Johnson: Net Revenue Share, By Segment, 2016
Figure 5.Johnson & Johnson: Net Revenue Share, By Geography, 2016
Figure 6.Bristol-Myers Squibb and Company/ Otsuka Pharmaceuticals: Net Revenues, 2014-2016 ($Million)
Figure7.Bristol-Myers Squibb and Company/ Otsuka Pharmaceuticals: Net Revenue Share, By Segment, 2016
Figure8.Bristol-Myers Squibb and Company/ Otsuka Pharmaceuticals: Net Revenue Share, By Geography, 2016
Figure9.AstraZeneca: Net Revenues, 2014-2016 ($Million)
Figure10.AstraZeneca: Net Revenue Share, By Segment, 2016
Figure 11.AstraZeneca: Net Revenue Share, By Geography, 2016
Figure 12.Eli Lilly: Net Revenues, 2014-2016 ($Million)
Figure 13.Eli Lilly: Net Revenue Share, By Segment, 2016
Figure 14.Eli Lilly: Net Revenue Share, By Geography, 2016
Figure 15.Allergan (Forest Labs)/ Geodon Ritcher: Net Revenues, 2014-2016 ($Million)
Figure 16.Allergan (Forest Labs)/ Geodon Ritcher: Net Revenue Share, By Segment, 2016
Figure 17.Allergan (Forest Labs)/ Geodon Ritcher: Net Revenue Share, By Geography, 2016

Research Methodology

We use both primary as well as secondary research for our market surveys, estimates and for developing forecast. Our research process commence by analyzing the problem which enable us to design the scope for our research study. Our research process is uniquely designed with enough flexibility to adjust according to changing nature of products and markets, while retaining core element to ensure reliability and accuracy in research findings. We understand both macro and micro-economic factors to evaluate and forecast different market segments.

Data Mining

Data is extensively collected through various secondary sources such as annual reports, investor presentations, SEC filings, and other corporate publications. We also refer trade magazines, technical journals, paid databases such as Factiva and Bloomberg, industry trade journals, scientific journals, and social media data to understand market dynamics and industry trends. Further, we also conduct primary research to understand market drivers, restraints, opportunities, challenges, and competitive scenario to build our analysis.

Data Collection Matrix

Data Collection Matrix

Supply Side

Demand Side

Primary Data Sources

  • Manufacturers
  • Distributors & Wholesalers
  • GPOs
  • Physicians/Specialist
  • Healthcare Providers
  • Consumers

Secondary Data Sources

  • Annual Reports/SEC Filings/ Investor Presentations/ Press Releases
  • Government/Associations Publications
  • Case Studies
  • Reference Customers

 

Market Modeling and Forecasting

We use epidemiology and capital equipment-based models to forecast market size of different segments at country and regional level.

  • Epidemiology-based Forecasting Model: This method uses epidemiology data gathered through various publications and from physicians to estimate population of patients, flow of treatment of individual disease and therapies. The data collected through this method includes statics on incidence of disease, population suffering from disease, and treatment population. This method is used to understand:
  • Number of patients for particular device or medical procedure and
  • Repeated use of particular device depending on health and condition of patient
  • Capital-based Forecasting Model: This method of forecasting is based on number of replacements, installed-based and new sales of capital equipment used in various healthcare and diagnostic centers. These three parameters are calculated and forecast is developed. Installation base is calculated as average number of units per facility; while sales for particular year is calculated from number of new and replace units. Secondary data is collected through various supply chain intermediaries and opinion leaders to arrive at installation and sales rate. These techniques help our analysts in validating market and developed market estimates and forecast.

We do forecast on basis of several parameters such as market drivers, market opportunities, industry trends government regulations, raw materials supply and trade dynamics to ensure relevance of forecast with market scenario. With increasing need to granulized information, we used bottom-up methodology for forecasting where we evaluate each regional segment differently and combined all forecast to develop final market forecast.

Data Validation

We believe primary research is a very important tool in analyzing and forecasting different markets. In order to make sure accuracy of our findings, our team conducts primary interviews at every stage of research to gain deep insights into current business environment and future trends and key developments in market. This includes use of various methods such as telephonic interviews, focus groups, face to face interviews and questionnaires to validate our research from all aspects. We validate our data through primary research from key industry leaders such as CEO, product managers, marketing managers, suppliers, distributors, and consumers are frequently interviewed. These interviews provide valuable insights which help us to have better market understanding besides validating our estimates and forecast.

Data Triangulation

Industry Analysis

Qualitative Data

Quantitative Data (2017-2025)

  • Market Dynamics (Drivers, Restraints, and Challenges)
  • Industry Trend Analysis
  • Market Opportunities
  • Government Policies and Regulations, Patent Analysis, and Reimbursement Policies
  • Porter’s Five Forces and PESTLE Analysis
  • Key Developments and Competitive Landscape
  • Market Assessment and Forecast
  • Market Assessment and Forecast, By Product
  • Market Assessment and Forecast, By Technology
  • Market Assessment and Forecast, By Application
  • Market Assessment and Forecast, By End User
  • Market Assessment and Forecast, By Region/Country

License Type

For Any Assistance

*
*
*